Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OlympusOCPNF +17.24%82 EV-to-EBIT is 21.97 as of Aug. 08, 2026, which is 5% below its 10-year median of 23.20. GuruFocus rates OCPNF with a GF Score™ of 82/100 and a GF Value™ of $16.26 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Olympus ranks worse than 52.03% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Olympus's Enterprise Value is $14,946 Mil.
Olympus's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $680 Mil. Therefore, Olympus's EV-to-EBIT for today is 21.97.
The historical rank and industry rank for Olympus's EV-to-EBIT or its related term are showing as below:
OCPNF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.07 Med: 23.2 Max: 61.14
Current: 21.97
During the past 13 years, the highest EV-to-EBIT of Olympus was 61.14. The lowest was 11.07. And the median was 23.20.
OCPNF's EV-to-EBIT is ranked worse than 52.03% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 19.13
vs OCPNF: 21.97
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Olympus's Enterprise Value for the quarter that ended in Mar. 2026 was $10,419 Mil.
Olympus's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $680 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olympus EV-to-EBIT Related Terms
Olympus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Olympus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Olympus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olympus EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Olympus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Olympus's EV-to-EBIT falls into.
Olympus's current Enterprise Value is $14,946 Mil.
Olympus's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $680 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olympus (OCPNF) has a EV-to-EBIT of 21.97 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Olympus and its competitors. This is near median its historical median of 23.20. Over the past decade, Olympus' EV-to-EBIT has ranged from 11.07 to 61.14. According to the industry distribution chart, Olympus ranks #244 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Olympus' EV-to-EBIT too high?
Olympus' current EV-to-EBIT of 21.97 is near median its 10-year median of 23.20. Over the past 10 years, this metric has ranged from a low of 11.07 to a high of 61.14. The Medical Devices & Instruments industry median EV-to-EBIT is 19.13. Olympus' value of 21.97 is 14.8% above this industry median. Based on the distribution chart, Olympus ranks #244 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Olympus has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #244 out of 469 companies for EV-to-EBIT. This places Olympus in the lower half of its industry. The industry median EV-to-EBIT is 19.13. Olympus' value of 21.97 is 14.8% above this benchmark. Historically, Olympus' own EV-to-EBIT has ranged from 11.07 to 61.14 over the past decade. While the company's 10-year median is 23.20 vs. the industry median of 19.13, Olympus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.13, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olympus's current EV-to-EBIT of 21.97 is 14.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Olympus and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olympus's current EV-to-EBIT is 21.97, which is near median its own 10-year median of 23.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (OCPNF) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.26, compared to a current price of $12.31 — trading 24.3% below its estimated fair value. The current EV-to-EBIT is 21.97, which is near median its 10-year median of 23.20 and 14.8% above the Medical Devices & Instruments industry median of 19.13. Olympus' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Olympus (OCPNF), the current EV-to-EBIT is 21.97 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Olympus (OCPNF) Overvalued in 2026?
Based on GuruFocus' analysis, Olympus stock appears to be undervalued.
The current stock price of $12.31 is trading 24.3% below its estimated GF Value™ of $16.26.
GuruFocus considers Olympus to be Modestly Undervalued.
Key valuation signals for OCPNF:
EV-to-EBIT: 21.97 (near median its 10-year median of 23.20)
GF Value™: $16.26 vs. price of $12.31 (24.3% below fair value)
Industry Position: 14.8% above the Medical Devices & Instruments median (#244 of 469)
No single metric tells the full story. See the OCPNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
82GF Score
Get the complete analysis for OCPNF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCPNF has been successfully added to your 
